Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF) patients could benefit from treatment for the first time. The company is a pioneer in ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The three major indexes slid in March and April as ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. David Kindness is a Certified Public ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. David Kindness is a Certified Public Accountant (CPA) and an expert in the fields of financial accounting ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals is riding high on analyst confidence, thanks to its leadership in NAV1.8 inhibitors and smart partnerships. Jefferies analyst Michael Yee recently reaffirmed a Buy rating, ...

Access Vertex stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.

UBS analyst Eliana Merle reaffirmed a Buy rating and a $582 price target for Vertex Pharmaceuticals, praising the adoption of ...

Elastic ("Elastic"), the Search AI Company, announced financial results for its fourth quarter and full fiscal year ended April 30, 2025. Fourth Quarter Fiscal 2025 Financial Highlights Total revenue ...

This was the stock's second consecutive day of gains.